---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Specific populations questions"
description: "Specific populations questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Is Opdivo safe and effective for children with lung cancer? Is Opdivo plus Yervoy safe and effective in older adults with NSCLC? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Specific populations questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Specific populations questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications: Specific populations](https://www.evicenter.com/medical-information/opdivo/specific-populations).

## Pediatric use

<a id="opdivo-pediatric"></a>

### Is Opdivo safe and effective for children with lung cancer?

> “The safety and effectiveness of OPDIVO have not been established in pediatric patients 
> with non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell 
> carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, hepatocellular 
> carcinoma, esophageal cancer, gastric cancer, gastroesophageal cancer and esophageal 
> adenocarcinoma.”

Source: [OPDIVO: OPDIVO, page 33, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=33)

## Specific populations

<a id="opdivo-elderly"></a>

### Is Opdivo plus Yervoy safe and effective in older adults with NSCLC?

> “Of the 576 patients with NSCLC who were randomized to OPDIVO in combination with ipilimumab, 
> 48% were 65 years or older and 10% were 75 years or older. No overall difference in safety 
> was reported between older patients and younger patients; however, there was a higher 
> discontinuation rate due to adverse reactions in patients aged 75 years or older (29%) relative 
> to all patients who received OPDIVO with ipilimumab (18%). Of the 396 patients in the primary 
> efficacy population (PD-L1 ≥1%) randomized to OPDIVO in combination with ipilimumab, the 
> hazard ratio for overall survival was 0.70 (95% CI: 0.55, 0.89) in the 199 patients younger than 
> 65 years compared to 0.91 (95% CI: 0.72, 1.15) in the 197 patients 65 years or older [see Clinical 
> Studies (14.3)].”

Source: [OPDIVO: OPDIVO, page 33, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=33)

> “Of the 361 patients with NSCLC who were randomized to OPDIVO in combination with 
> ipilimumab and platinum-doublet chemotherapy, 51% were 65 years or older and 10% were 
> 75 years or older. No overall difference in safety was reported between older patients and 
> younger patients; however, there was a higher discontinuation rate due to adverse reactions 
> in patients aged 75 years or older (43%) relative to all patients who received OPDIVO with 
> ipilimumab and chemotherapy (24%). For patients aged 75 years or older who received 
> chemotherapy only, the discontinuation rate due to adverse reactions was 16% relative to all 
> patients who had a discontinuation rate of 13%. Based on an updated analysis for overall survival, 
> of the 361 patients randomized to OPDIVO in combination with ipilimumab and platinum-doublet 
> chemotherapy, the hazard ratio for overall survival was 0.61 (95% CI: 0.47, 0.80) in the 176 patients 
> younger than 65 years compared to 0.73 (95% CI: 0.56, 0.95) in the 185 patients 65 years or older 
> [see Clinical Studies (14.5)].”

Source: [OPDIVO: OPDIVO, page 33, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=33)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
